MAM
AXSM icon

Meeder Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Meeder Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92K Buy
+16
New +$3.47K ﹤0.01% 876
2026
Q1 		– Sell
-30
Closed -$5.48K – 901
2025
Q4 		$5.48K Buy
30
+2
+7% +$279 ﹤0.01% 783
2025
Q3 		$3.4K Buy
+28
New +$3.15K ﹤0.01% 730
2025
Q2 		– Sell
-14
Closed -$1.63K – 864
2025
Q1 		$1.63K Buy
+14
New +$1.59K ﹤0.01% 878
2024
Q3 		– Sell
-47
Closed -$3.78K – 845
2024
Q2 		$3.78K Buy
+47
New +$3.48K ﹤0.01% 806
2020
Q4 		– Sell
-1,504
Closed -$108K – 1884
2020
Q3 		$108K Sell
1,504
-307
-17% -$23.9K 0.01% 763
2020
Q2 		$149K Buy
1,811
+253
+16% +$19.5K 0.01% 661
2020
Q1 		$92K Buy
1,558
+134
+9% +$10.9K 0.01% 733
2019
Q4 		$147K Buy
1,424
+637
+81% +$25.7K 0.01% 687
2019
Q3 		$17K Buy
+787
New +$20.2K ﹤0.01% 1361
2019
Q2 		– Sell
-146
Closed -$2K – 2031
2019
Q1 		$2K Sell
146
-2,387
-94% -$22.2K ﹤0.01% 1538
2018
Q4 		$7K Sell
2,533
-1,501
-37% -$4.94K ﹤0.01% 1327
2018
Q3 		$14K Buy
4,034
+2,796
+226% +$8.29K ﹤0.01% 1092
2018
Q2 		$3.96K Buy
1,238
+43
+4% +$133 ﹤0.01% 1319
2018
Q1 		$3K Sell
1,195
-159
-12% -$476 ﹤0.01% 1314
2017
Q4 		$8K Buy
1,354
+519
+62% +$2.62K ﹤0.01% 1179
2017
Q3 		$5K Buy
835
+310
+59% +$1.66K ﹤0.01% 1255
2017
Q2 		$3K Hold
525
– – ﹤0.01% 1311
2017
Q1 		$2K Sell
525
-75
-13% -$358 ﹤0.01% 1347
2016
Q4 		$4K Buy
+600
New +$4.21K ﹤0.01% 875

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Meeder Asset Management's AXSM Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 16 shares worth $3.92K. The stake represents ﹤0.01% of the portfolio and ranks #876 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in AXSM as recently as Q4 2025.

Meeder Asset Management first reported a position in AXSM in Q4 2016 and has held it in 20 quarters since. The position peaked at $149K in Q2 2020. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Meeder Asset Management held 16 shares of Axsome Therapeutics worth $3.92K as of Q2 2026.
  • Axsome Therapeutics was a new Meeder Asset Management position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #876 holding.
  • Meeder Asset Management first reported a position in Axsome Therapeutics in Q4 2016 and has held it in 20 quarters since.
  • Meeder Asset Management's Axsome Therapeutics position peaked at $149K in Q2 2020.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.